EPOS-IASIS (www.epos-iasis.com) is a vibrant nano-biotechnology SME in Cyprus, established in 2006 as the First Prize Winner of the CyEntrepreneurshipCompetition (CyEC). The vision of EPOS-IASIS is to become a long-standing reliable partner in health care and establish itself as a leading research, development and education enterprise in the European environment. EPOS has amassed expertise in the translational nanotheranostics, molecular imaging and cell-based technologies, with emphasis on hybrid (cell+electronics) systems, harnessing molecules and light for faster diagnosis and better prognosis. EPOS has established the sole mulrimodal In Vivo imaging platfomr on the island (mCT-3DOI-FMT) and the first setting for BRET/FRET technology in the region. It is considered a regional leader in translational nanotheranostics. In the first 13 years of life, EPOS has co-ordinated or participated as a major par in numerous national and one major FP7-IAPP and H2020 grants, bridging the academic with the entrepreneurial spirit across sectors, amassing more than 5M Euros, including MDCAs, HORIZON-WIDESPREAD-Teaming I (Precision Technologies) and FETOpen. EPOS has secured 1 EPO, 2 USPO and1 PCT patents in theranostics, new CNT-delivery systems for brain tumors and on multifunctional conjugates for metastatic Cancer. The strategy of the company is to partner with other flexible teams through the research and development phases and with well-established pharmaceutical and biomedical engineering firms for the testing, productions and selling of our products.
Recognized as a leading regional nanobiotechnology R&D SME in its field, EPOS collaborates with over 25 organisations worldwide. EPOS’s collaborators range from world-renowned academic institutions, in Europe the United States, Australia and Japan to large industrial partners, government organisations, and small and medium size enterprises that are seeking solutions to translational nanomedicine and molecular oncology problems. For example, the enterprise has strong collaborations with the National Medical and Public Health Services and the Brain Tumour Patient Association, which are supporting its research activities but are also partnering the expertise of EPOS in the establishment of a National Brain Tumour Biobank, paving the way towards advanced molecular therapeutics.